Three Major Cannabis MSOs Face Federal Class Action Over Medical Claims

Three of the country's largest multi-state cannabis operators are facing a federal class action lawsuit alleging they made false medical claims about their products, according to a complaint filed Monday in federal court.

The lawsuit targets Chicago-based Cresco Labs, Green Thumb Industries, and Verano Holdings—collectively representing billions in market capitalization—on behalf of 42 customers spanning a dozen states. The complaint alleges the companies caused "tragedy and human misery" through unsubstantiated health claims about their cannabis products.

The legal challenge arrives as the cannabis industry faces heightened scrutiny over marketing practices, particularly claims that blur the line between wellness products and medical treatments. Federal regulators have historically been aggressive in policing health claims for products containing cannabis compounds, even in states where marijuana is legal.

The Allegations

While specific details of the purported false claims weren't immediately available, the lawsuit's scope—covering customers in 12 states—suggests a pattern of marketing practices across multiple jurisdictions. The three companies named operate dispensaries and cultivation facilities in numerous states, making them among the most visible players in the legal cannabis market.

Cresco Labs operates the Sunnyside dispensary chain and owns several prominent cannabis brands. Green Thumb Industries runs the RISE dispensary network and manufactures products under brands including Beboe and Dogwalkers. Verano Holdings operates Zen Leaf stores and produces a range of cannabis products sold across its footprint.

The complaint filed in federal court represents a significant legal risk for the operators, as class action lawsuits can result in substantial settlements even when companies dispute the underlying claims. For context, the dietary supplement industry has paid hundreds of millions in settlements over similar allegations about unsubstantiated health claims in recent years.

Industry Marketing Under the Microscope

Cannabis companies operate in a regulatory gray zone when it comes to marketing. The FDA has repeatedly warned companies against making therapeutic claims about CBD products without approval, and the agency's position extends to other cannabis compounds. State regulators have also cracked down on dispensaries and manufacturers making specific medical claims without proper substantiation.

The lawsuit underscores the tension between consumer expectations—many medical marijuana patients use cannabis specifically for health conditions—and the strict legal requirements around making health claims. Even in states with medical marijuana programs, companies face restrictions on what they can say about their products' therapeutic benefits.

Industry observers have noted that some cannabis companies adopted marketing language from the supplement and wellness industries, which has historically drawn regulatory attention. The line between describing a product's properties and making an explicit medical claim can be razor-thin, and companies without robust compliance programs may inadvertently cross it.

What's Next

The three companies named in the lawsuit have not yet publicly responded to the allegations. Given the size and prominence of the defendants, the case will likely be closely watched by other cannabis operators evaluating their own marketing practices.

Class action lawsuits typically proceed through a certification phase, where the court determines whether the case can move forward as a class action. If certified, the case could expand to include additional customers beyond the initial 42 plaintiffs.

The timing of the lawsuit is notable as the cannabis industry pushes for federal legalization and seeks to establish itself as a legitimate sector. High-profile legal challenges over business practices could complicate those efforts, particularly if they suggest inadequate self-regulation.

For the three MSOs involved, the immediate priority will be assessing their exposure and determining whether to fight the claims or pursue an early settlement. The outcome could have implications across the industry, potentially prompting other large operators to review and revise their marketing materials.

---

This article is based on original reporting by ganjapreneur.com.